Eine Studie zur Bewertung der Wirksamkeit und Sicherheit von Obinutuzumab bei Teilnehmern mit systemischem Lupus erythematodes (ALLEGORY)
Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit von Obinutuzumab bei Patienten mit systemischem Lupus erythematodes
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, C1015ABO
- Organizacion Medica de Investigacion
-
Buenos Aires, Argentinien, C1111AAJ
- DOM Centro de Reumatología
-
San Miguel, Argentinien, T4000AXL
- Centro de Investigaciones Médicas Tucuman
-
-
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40150-150
- Ser Servicos Especializados Em Reumatologia
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30130-100
- Hospital das Clinicas - UFMG
-
Belo Horizonte, Minas Gerais, Brasilien, 30150-221
- Santa Casa de Misericordia
-
Juiz de Fora, Minas Gerais, Brasilien, 36010-570
- Centro Mineiro de Pesquisa - CMIP
-
-
Paraná
-
Curtiba, Paraná, Brasilien, 80030-110
- Centro de Estudos em Terapias Inovadoras ? CETI
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brasilien, 14051-140
- Hospital das Clinicas - FMUSP Ribeirao Preto
-
São Bernardo do Campo, São Paulo, Brasilien, 09715-090
- Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*
-
-
-
-
-
Paris, Frankreich, 75651
- Ch Pitie Salpetriere
-
-
-
-
Lazio
-
Rome, Lazio, Italien, 00168
- Policlinico Universitario Agostino Gemelli
-
-
Lombardy
-
Milan, Lombardy, Italien, 20132
- IRCCS S. Raffaele
-
-
Tuscany
-
Pisa, Tuscany, Italien, 56126
- A.O. Universitaria Pisana
-
-
Veneto
-
Cona (Ferrara), Veneto, Italien, 44124
- Azienda Ospedaliero-Universitaria Di Ferrara Arcispedale Santanna
-
Padova, Veneto, Italien, 35128
- Uni Di Padova
-
-
-
-
Coahuila
-
Torreón, Coahuila, Mexiko, 27000
- Centro de Investigacion Alberto Bazzoni S.A. de C.V.
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Mexiko, 21100
- Unidad de Reumatologia Rehabilitacion Integral
-
-
Mexico CITY (federal District)
-
Mexico City, Mexico CITY (federal District), Mexiko, 11850
- Centro de Investigación y Tratamiento Reumatológico S.C.
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexiko, 64460
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
-
-
-
-
Auckland, Neuseeland, 2025
- Middlemore Hospital
-
Wellington, Neuseeland, 0621
- Wellington Hospital
-
-
-
-
-
Arequipa, Peru, 04000
- Hogar Clínica San Juan de Dios
-
Lima, Peru
- Instituto de Ginecología y Reproducción
-
Lima, Peru, 15431
- Clínica San Juan Bautista CSJB
-
San Isidro, Peru, L27 Lima
- Clinica El Golf
-
Trujillo, Peru, 13008
- Clinica San Antonio;Investigaciones Trujillo S.A.C.
-
-
-
-
-
Bydgoszcz, Polen, 85-168
- Szpital Uniwersytecki
-
Poznan, Polen, 61-397
- Prywatna Praktyka Lekarska
-
Poznan, Polen, 61-545
- Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM
-
Poznan, Polen, 60-218
- Medyczne Centrum Hetmanska
-
Warsaw, Polen, 02-118
- Rheuma Medicus Zaklad Opieki Zdrowotnej
-
Warsaw, Polen, 00-874
- MICS Centrum Medyczne Warszawa
-
Wroc?aw, Polen, 52-210
- REUMATOP Grzegorz Rozumek, Karin Pistorius Spó?ka Jawna
-
-
-
-
Bashkortostan Republic
-
Ufa, Bashkortostan Republic, Russland, 450005
- Republican clinical hospital named after G.G. Kuvatov
-
-
Moscow Oblast
-
Moscow, Moscow Oblast, Russland, 115522
- Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Russland, 197341
- FGBU ?Federal Medical and Research Center named after V.A.Almazov? Russian Ministry of Health
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitario Vall d'Hebron
-
Madrid, Spanien, 28007
- Hospital General Universitario Gregorio Marañon
-
-
-
-
-
Cape Town, Südafrika, 7500
- Panorama Medical Center
-
Pretoria, Südafrika, 0002
- Emmed Research
-
Somerset West, Südafrika, 7130
- Clinical Trials Network Helderberg
-
Umhlanga, Südafrika, 4319
- Dr Asokan Naidoo
-
-
-
-
-
Prague, Tschechien, 128 50
- Revmatologicky Ustav
-
-
-
-
Alabama
-
Anniston, Alabama, Vereinigte Staaten, 36207
- Pinnacle Research Group
-
-
Arkansas
-
Searcy, Arkansas, Vereinigte Staaten, 72143
- Unity Health - White County Medical Center- Rheumatology
-
-
California
-
Fullerton, California, Vereinigte Staaten, 92835
- Providence Medical Foundation
-
-
Florida
-
Aventura, Florida, Vereinigte Staaten, 33180
- Arthritis & Rheumatism
-
-
Michigan
-
Lansing, Michigan, Vereinigte Staaten, 48911
- Great Lakes Center of Rheumatology
-
Troy, Michigan, Vereinigte Staaten, 48047
- Clinical Research Institute of Michigan, LLC
-
-
New York
-
Great Neck, New York, Vereinigte Staaten, 11021
- Northwell Health Division of Rheumatology
-
New York, New York, Vereinigte Staaten, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Joint & Muscle Research Institute
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43212
- The Ohio State University Wexner Medical Center
-
Middleburg Heights, Ohio, Vereinigte Staaten, 44130
- Paramount Medical Research & Consulting, LLC
-
-
Texas
-
Colleyville, Texas, Vereinigte Staaten, 76034
- Precision Comprehensive Clinical Research Solutions
-
El Paso, Texas, Vereinigte Staaten, 79902
- Texas Arthritis Center
-
Houston, Texas, Vereinigte Staaten, 77054
- Prolato Clinical Research Center
-
-
-
-
-
Cambridge, Vereinigtes Königreich, CB2 2QQ
- Addenbrooke'S Hospital
-
Leeds, Vereinigtes Königreich, LS1 3EX
- Chapel Allerton Hospital
-
London, Vereinigtes Königreich, SE1 9RT
- Guy's Hospital
-
London, Vereinigtes Königreich, NW3 2QG
- Royal Free Hospital
-
Manchester, Vereinigtes Königreich, M13 9WL
- Manchester Royal Infirmary
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria >=12 weeks prior to screening
- Anti-nuclear antibody (ANA) >=1:80, or anti-dsDNA and/or anti-Sm antibodies above the upper limit of normal (ULN), as determined by the central laboratory at screening
- Low C3 or low C4 or low CH50 complement as determined by the central laboratory at screening
- High disease activity at screening, based on; BILAG-2004 (Category A disease in >=1 organ system and/or Category B disease in >=2 organ systems), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (score >=8) and Physician's Global Assessment (PGA) (score >=1.0 on a 0 to 3 visual analogue scale [VAS])
- High disease activity on Day 1, based on; SLEDAI-2K (score >=8) and PGA (score >=1.0 on a 0 to 3 VAS)
- Current receipt of >=1 of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroid (OCS), antimalarials, conventional immunosuppressants
- Other inclusion criteria may apply
- The Medical Monitor may be consulted if there are any questions related to eligibility criteria
Exclusion Criteria:
- Pregnancy or breastfeeding
- Presence of significant lupus-associated renal disease and/or renal impairment
- Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
- Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
- Known active infection of any kind or recent major episode of infection
- Intolerance or contraindication to study therapies
- Other exclusion criteria may apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Obinutuzumab
Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26. |
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
Andere Namen:
Acetaminophen 650-1000 mg will be administered as premedication prior to infusions. Diphenhydramine 50 mg will be administered as premedication prior to infusions. Methylprednisolone 80 mg IV will be administered as premedication prior to infusions. |
|
Placebo-Komparator: Placebo
Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26. |
Acetaminophen 650-1000 mg will be administered as premedication prior to infusions. Diphenhydramine 50 mg will be administered as premedication prior to infusions. Methylprednisolone 80 mg IV will be administered as premedication prior to infusions. Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52
Zeitfenster: At Week 52
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by >=1 new British Isles Lupus Assessment Group (BILAG) A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52
Zeitfenster: At Week 52
|
Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52
Zeitfenster: From Week 40 through Week 52
|
Sustained OCS was defined as all of the following: 1) No treatment with prednisone >7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders. |
From Week 40 through Week 52
|
|
Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52
Zeitfenster: From Week 40 Through Week 52
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
From Week 40 Through Week 52
|
|
Percentage of Participants With SRI(6) Response at Week 52
Zeitfenster: At Week 52
|
Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Time to BILAG Flare Over 52 Weeks
Zeitfenster: At Week 52
|
BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare. |
At Week 52
|
|
Percentage of Participants Who Achieved SRI(4) at Week 24
Zeitfenster: At Week 24
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 24
|
|
Percentage of Participants Who Achieved Clinical SRI(4) at Week 52
Zeitfenster: At Week 52
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids
Zeitfenster: At Week 52
|
Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of >=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS; 4) Prednisone <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52
Zeitfenster: At Week 52
|
LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K <=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS <=1; 4) Current prednisone dose <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52
Zeitfenster: At Week 52
|
DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS <0.5; 3) Current prednisone dose <=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders. |
At Week 52
|
|
Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52
Zeitfenster: Baseline, Weeks 24 and 52
|
The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model. |
Baseline, Weeks 24 and 52
|
|
Change in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52
Zeitfenster: Baseline, Weeks 24 and 52
|
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model. |
Baseline, Weeks 24 and 52
|
|
Change in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52
Zeitfenster: Baseline, Weeks 24 and 52
|
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model. |
Baseline, Weeks 24 and 52
|
|
Change in Active Joint Count From Baseline to Weeks 24 and 52
Zeitfenster: Baseline, Weeks 24 and 52
|
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model. |
Baseline, Weeks 24 and 52
|
|
Percentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline
Zeitfenster: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders. |
At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
|
Percentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit
Zeitfenster: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders. |
At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
|
Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52
Zeitfenster: From Week 40 through Week 52
|
Sustained OCS was defined as all of the following: 1) No treatment with prednisone >5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders. |
From Week 40 through Week 52
|
|
Cumulative Corticosteroid Use Through Week 52
Zeitfenster: Up to Week 52
|
Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant. |
Up to Week 52
|
|
Annualized Flare Rate Through Week 52
Zeitfenster: Up to Week 52
|
BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period). |
Up to Week 52
|
|
Number of Participants With Adverse Events (AEs)
Zeitfenster: Up to Week 52
|
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. |
Up to Week 52
|
|
Number of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia
Zeitfenster: Up to Week 52
|
AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade >=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions. |
Up to Week 52
|
|
Maximum Serum Concentration (Cmax) of Obinutuzumab
Zeitfenster: From Weeks 0-24 and Weeks 24-52
|
Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here. |
From Weeks 0-24 and Weeks 24-52
|
|
Trough Concentration (Ctrough) of Obinutuzumab
Zeitfenster: From Weeks 0-24 and Weeks 24-52
|
Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals. |
From Weeks 0-24 and Weeks 24-52
|
|
Area Under the Concentration-time Curve (AUC) of Obinutuzumab
Zeitfenster: Week 0-52
|
AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks. |
Week 0-52
|
|
Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab
Zeitfenster: Up to Week 52
|
Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here. |
Up to Week 52
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Clinical Trials, Hoffmann-La Roche
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Bindegewebserkrankungen
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Haut- und Bindegewebserkrankungen
- Lupus erythematodes, systemisch
- Organische Chemikalien
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Anilides
- Amides
- Anilinverbindungen
- Amine
- Acetanilide
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Benzolderivate
- Schwangerschaften
- Ethylamine
- Prednisolon
- Benzhydrylverbindungen
- Acetaminophen
- Methylprednisolon
- Diphenhydramin
- Obinutuzumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CA42750
- 2020-005760-57 (EudraCT-Nummer)
- 2023-504774-38-00 (Andere Kennung: EU CT Number)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .